Home Health GSK in talks to buy cancer biotech Nuvalent for more than $9bn
Health

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

GSK in talks to buy cancer biotech Nuvalent for more than $9bn
Key Points

A deal will rank as one of UK drugmaker’s biggest as biotech M&A activity accelerates this year

A deal will rank as one of UK drugmaker’s biggest as biotech M&A activity accelerates this year
GSK (ORG) Nuvalent (LOCATION) UK (LOCATION)
Originally published by Financial Times Read original →